CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The new online Learning Center with new content can still be found under the “Training” folder on ...